MedTrace Logo

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

NCT06373133 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-04-18

No results posted yet for this study

Summary

To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.

Conditions

Interventions

DRUG

SHR-8068

1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w

DRUG

Adebrelimab

1200mg, ivgtt, d1, q3w

DRUG

BP102

7.5mg/kg, ivgtt, d1, q3w

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-11-01
Completion
2026-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06373133 on ClinicalTrials.gov